| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,882 | -5,014 |
| Depreciation | 3 | 2 |
| Non-cash operating lease expense | 84 | 62 |
| Recurring fair value measurements of liabilities | -323 | 9 |
| Issuance of common stock to vendors | 0 | 0 |
| Write-off of deferred equity issuance costs | 75 | 75 |
| Loss on disposal of property and equipment | 0 | 0 |
| Stock-based compensation and related charges | 228 | 138 |
| Other | 61 | - |
| Prepaid and other current assets and other noncurrent assets | 537 | 18 |
| Accounts payable and accrued liabilities | 255 | 1,210 |
| Accrued compensation and benefits | -101 | -530 |
| Operating lease liabilities | -90 | -66 |
| Net cash used in operating activities | -7,703 | -4,150 |
| Payments on insurance financing debt | 180 | 80 |
| Proceeds from issuance of common stock and warrants | 0 | 0 |
| Proceeds from the exercise of warrants | 3,909 | 1 |
| Payment of warrant inducement issuance costs | 445 | 0 |
| Payment of equity issuance costs | 178 | 178 |
| Proceeds from issuance of common stock under employee stock purchase plan | 3 | 3 |
| Shares withheld for payment of employee withholding tax liability | 0 | 0 |
| Net cash provided by financing activities | 3,109 | -254 |
| Net decrease in cash, cash equivalents and restricted cash | -4,594 | -4,404 |
| Cash and cash equivalents at beginning of period | 9,847 | - |
| Cash and cash equivalents at end of period | 5,253 | - |
PALISADE BIO, INC. (PALI)
PALISADE BIO, INC. (PALI)